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Abstract
The development of new therapies has a rich history, evolves quickly with societal trends, and will have an exciting
future. The last century has seen an exponential increase in complex interactions between medical practitioners,
pharmaceutical companies, governments and patients. We believe technology and societal expectations will open
up the opportunity for more individuals to participate as information becomes more freely available and inequality
less acceptable. Corporations must recognize that usual market forces do not function ideally in a setting where
health is regarded as a human right, and as modern consumers, patients will increasingly take control of their own
data, wellbeing, and even the means of production for developing their own treatments. Ethics and legislation will
increasingly impact the processes that facilitate drug development, distribution and administration. This article
collection is a cross-journal collaboration, between the Journal of Pharmaceutical Policy and Practice (JoPPP) and
BMC Medicine that seeks to cover recent advances in drug development, medicines use, policy and access with
high clinical and public health relevance in the future.
The Medicine and the Future of Health article collection is a joint collection between BMC Medicine and Journal of
Pharmaceutical Policy and Practice. Therefore, this Editorial by the guest editors has been published in both journals.
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Drug shortages
Any vision of the future requires an appreciation of the
past. Historically, the availability of medical treatments has
paralleled life’s other “luxuries” and so was only available to
the few. However, most remedies and would-be cures were
not effective prior to the 20th century, with few notable ex-
ceptions. Among these, digitalis, an extract from the purple
foxglove (Digitalis purpurea) was first used in the dark
ages as a poison until its discovery in 1775 for the treat-
ment of heart failure [1]. More recently, the antimalarial
drug artemether was extracted from the herb Qinghao,
which had been used in China for over 2000 years [2].
In the 1920s, the emergence of more consistently ef-
fective pharmaceutical agents began, led by analgesics,
including aspirin and morphine, insulin, and anti-
infective agents such as sulphonamides and penicillin.
However, it was soon realised that these potent new che-
micals also carried risks. In 1937, investigators discov-
ered, via a spate of reports to the American Medical
Association, that an improperly prepared mixture of
Elixir Sulfanilamide had killed over 100 people, prompt-
ing public outrage. This disaster led to the 1938 Federal
Food, Drug, and Cosmetic Act to ensure that new drugs
would be tested on animals and reviewed by the Food
and Drug Administration. Subsequent amendments to
the 1938 act introduced prescriptions for certain drugs
(1951) and legislated for clinical trials (1962) [3]. Today,
the post marketing surveillance of new medicines is much
more sophisticated, and includes physician reports, patient
outreach, Risk Evaluation and Mitigation Strategy pro-
grams, and the monitoring of electronic medical records.
Such systems allow for enhanced safety via warning sys-
tems and the orderly withdrawal of drugs, though even
this system suffers global inconsistencies [4].
As the pharmaceutical industry developed more effect-
ive medicines, quality of life of those suffering from many
diseases clearly improved, as corticosteroids controlled
* Correspondence: mdcfda@nus.edu.sg
1Infectious Disease Division, Department of Medicine, National University
Hospital; National University Health Systems, 1E Kent Ridge Rd, Singapore
119228, Singapore
2Yong Loo Lin School of Medicine, National University of Singapore,
Singapore, Singapore
Full list of author information is available at the end of the article
Medicine and the Future of Health
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Fisher et al. BMC Medicine  (2016) 14:169 
DOI 10.1186/s12916-016-0717-0
inflammatory diseases, antihistamines controlled allergies,
xanthines aided asthma patients, and options were offered
to mental illness sufferers. Indeed, the human life span
lengthened as infectious disease, heart disease, lung
disease, and increasingly, cancer could be ameliorated
through a combination of public health initiatives and bet-
ter medicines. Today, medicines are intrinsic in all our lives,
with almost half of US citizens taking a prescription medi-
cine in the last 30 days [5]. However, rather than treating
true disease pathology, the most intensively treated condi-
tions at the population level in the US are pain, high choles-
terol, depression and diabetes, arguably compensating for
lifestyle changes brought about by dietary changes and a
more sedentary lifestyle and due, in part, to the business
models that encourage “blockbuster” drugs.
Medicines need to be readily available and affordable,
however, unfortunately, there is an unacceptable level of
medicine shortages across countries of all income levels.
Currently, over 2 billion people do not have access to
medicines [6]. In this context, the United Nations has
set up a high-level forum to find ways to promote access
to affordable medicines [7]. Iyengar et al. describe the
driving factors behind access barriers and propose po-
tential mitigation strategies [8].
There is widespread recognition that the existing global
systems for innovation and access to medicines need re-
form. “Market failures” prevent new drugs from being de-
veloped that would primarily benefit the global poor,
while factors such as high prices of medicines, weak health
systems, corruption, and a lack of transparency, hinder ef-
forts to distribute the medicines already available [9].
Community pharmacy triage services are emerging as a
potential solution in a number of countries [10].
Access to medicines was once considered an issue con-
fined to low- and middle-income countries; however, it is
increasingly clear that access issues are also prevalent in
high-income countries. For example, in the European
Union, almost 50 % of drug expenditure is on cancer
drugs [11, 12]. In the future, it is likely that access may be
improved for cheaper generic options, but concerns re-
main over whether “biosimilars” will successfully fill the
same role [13].
Antibiotics, as a class, and their usage warrant consid-
eration in their own right, especially given that their effi-
cacy relies partly upon the extent of their use in other
patients. Dyer et al. showed that one-third of US anti-
biotic prescriptions are inappropriate, and he warns us
that we may be taking our once potent antibiotics for
granted [14]. Because the drug targets and the class itself
originate from nature, Woon et al. make the case that
we must consider the effective use of antibiotics as akin
to managing a delicate ecosystem [15].
Ironically, given their overuse in the US, antibiotics
are a case study in the difficulty of access to drugs in
low- and middle-income countries. Articles to be in-
cluded in JoPPP will consider the national and global
strategies needed to improve access, raise antibiotic
quality, diffuse accurate diagnostics to the point of care,
and ensure local stewardship for the sustainable opti-
misation of antibiotic use [16]. The understanding of
these factors and usefulness of interventions through in-
centives and legislation will continue to evolve. Further
affecting the usage of antibiotics will be more rapid
point-of-care diagnostics, vaccines, faecal microbiota
transplantation, probiotics and other novel approaches
to infectious diseases. It is unlikely, however, that alter-
native technologies will displace the need for the con-
ventional class and its development.
Looking forward, IMS Health has predicted that global
spending on pharmaceuticals will increase by 30 % from
2015 to 2020, to US$ 1.4 trillion, due in part to improved
access, breakthrough innovations and cheaper drugs. A
large portion of the growth is also occurring in India,
China, Brazil and Indonesia, the so called “pharmemer-
ging markets”, in contrast to the US, where they predict
more than 90 % of drugs purchased will be generics [17].
“Unfairness” in health is becoming increasingly un-
acceptable as a social norm. People should not be
treated differently because of individual demographic
factors; with the right information in hand, patients will
increasingly be treated according to their need as
Norheim et al. explore [18]. Such “unfairness” within
countries is easier to address compared to global health
corruption, a covert exploitation of people and resources
which will require concentrated efforts to expose. In a
forum article, Mackey and a multidisciplinary panel dis-
cuss the ways in which corruption affects global health
at all levels, and explore the potential solutions in a
post-2015 development agenda [19].
In the future, it is very likely that the use of medicines
will be greatly influenced by technology, consumer edu-
cation and self-awareness regarding lifestyle and diseases
[20]. Technology will be a key driver for change in the
future, enhancing the medical skillset of healthcare pro-
fessionals facilitating updates and change in parallel with
consumers [21]. This could influence the way people use
medicines and how healthcare professionals manage pa-
tients. Novel change could include tailor-made drugs on
the basis of pharmacogenomic data or medicines manu-
factured locally and on demand through 3D printing
[22]. Future personalised sensors could measure clinical
parameters and blood biomarkers transmitting data in
real time to a cloud or, for instance, sending alerts when
a stroke is in its earliest stages [23].
We will continue to feature articles addressing how
medicine might be expected to evolve to be more individ-
ual patient centred. A forthcoming Forum article from
leading thinkers in the area will consider the opportunity
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for the “data shadow” of smartphones to aid in detecting
depression, for patient-reported outcomes to improve self-
management, for clinical trials to make their quantum
leap, and for the value perceived by patients to flow back
into the learning health system, perhaps supported by new
forms of machine learning.
Beyond the colourful history that belongs to the emer-
gence of pharmaceuticals in the last century there will
be an ongoing evolution in response to changing needs
driven largely by consumer demand and expectations.
Implicit in the very commission of this body of work
risks supporting a paternalistic notion that “experts” can
set the agenda for the future of medicine. The truth is
quite the opposite where, in this era of information,
“citizen health hackers” [24] may lead patients to self-
experiment at a faster pace than traditional players via
digital platforms and a mantra to experiment beyond the
traditional confines of medicine. Control of the music
industry and the lay press has moved to the consumer.
Such a move in the field of medicines might lead to accel-
erated discoveries and innovation that could theoretically
outpace the entrenched players providing consumer bene-
fits via lower prices and more rapid access as well as glo-
bal equity. If we let patients help, they may well lead us
into the future of medicine.
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